Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples

Elizabeth S. Hecht, Elizabeth H. Scholl, S. Hunter Walker, Amber D. Taylor, William Arthur Cliby, Alison A. Motsinger-Reif, David C. Muddiman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

An early-stage, population-wide biomarker for ovarian cancer (OVC) is essential to reverse its high mortality rate. Aberrant glycosylation by OVC has been reported, but studies have yet to identify an N-glycan with sufficiently high specificity. We curated a human biorepository of 82 case-control plasma samples, with 27%, 12%, 46%, and 15% falling across stages I-IV, respectively. For relative quantitation, glycans were analyzed by the individuality normalization when labeling with glycan hydrazide tags (INLIGHT) strategy for enhanced electrospray ionization, MS/MS analysis. Sixty-three glycan cancer burden ratios (GBRs), defined as the log10 ratio of the case-control extracted ion chromatogram abundances, were calculated above the limit of detection. The final GBR models, built using stepwise forward regression, included three significant terms: OVC stage, normalized mean GBR, and tag chemical purity; glycan class, fucosylation, or sialylation were not significant variables. After Bonferroni correction, seven N-glycans were identified as significant (p <0.05), and after false discovery rate correction, an additional four glycans were determined to be significant (p <0.05), with one borderline (p = 0.05). For all N-glycans, the vectors of the effects from stages II-IV were sequentially reversed, suggesting potential biological changes in OVC morphology or in host response.

Original languageEnglish (US)
Pages (from-to)4394-4401
Number of pages8
JournalJournal of Proteome Research
Volume14
Issue number10
DOIs
StatePublished - Oct 2 2015

Fingerprint

Ovarian Neoplasms
Polysaccharides
Plasmas
Neoplasms
Accidental Falls
Glycosylation
Electrospray ionization
Biomarkers
Individuality
Labeling
Limit of Detection
Ions
Mortality

Keywords

  • cancer biomarker
  • human plasma
  • INLIGHT
  • N-linked glycosylation
  • ovarian cancer
  • relative quantification

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. / Hecht, Elizabeth S.; Scholl, Elizabeth H.; Walker, S. Hunter; Taylor, Amber D.; Cliby, William Arthur; Motsinger-Reif, Alison A.; Muddiman, David C.

In: Journal of Proteome Research, Vol. 14, No. 10, 02.10.2015, p. 4394-4401.

Research output: Contribution to journalArticle

Hecht, Elizabeth S. ; Scholl, Elizabeth H. ; Walker, S. Hunter ; Taylor, Amber D. ; Cliby, William Arthur ; Motsinger-Reif, Alison A. ; Muddiman, David C. / Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. In: Journal of Proteome Research. 2015 ; Vol. 14, No. 10. pp. 4394-4401.
@article{20845cd83cce4dd5a961e9687901463a,
title = "Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples",
abstract = "An early-stage, population-wide biomarker for ovarian cancer (OVC) is essential to reverse its high mortality rate. Aberrant glycosylation by OVC has been reported, but studies have yet to identify an N-glycan with sufficiently high specificity. We curated a human biorepository of 82 case-control plasma samples, with 27{\%}, 12{\%}, 46{\%}, and 15{\%} falling across stages I-IV, respectively. For relative quantitation, glycans were analyzed by the individuality normalization when labeling with glycan hydrazide tags (INLIGHT) strategy for enhanced electrospray ionization, MS/MS analysis. Sixty-three glycan cancer burden ratios (GBRs), defined as the log10 ratio of the case-control extracted ion chromatogram abundances, were calculated above the limit of detection. The final GBR models, built using stepwise forward regression, included three significant terms: OVC stage, normalized mean GBR, and tag chemical purity; glycan class, fucosylation, or sialylation were not significant variables. After Bonferroni correction, seven N-glycans were identified as significant (p <0.05), and after false discovery rate correction, an additional four glycans were determined to be significant (p <0.05), with one borderline (p = 0.05). For all N-glycans, the vectors of the effects from stages II-IV were sequentially reversed, suggesting potential biological changes in OVC morphology or in host response.",
keywords = "cancer biomarker, human plasma, INLIGHT, N-linked glycosylation, ovarian cancer, relative quantification",
author = "Hecht, {Elizabeth S.} and Scholl, {Elizabeth H.} and Walker, {S. Hunter} and Taylor, {Amber D.} and Cliby, {William Arthur} and Motsinger-Reif, {Alison A.} and Muddiman, {David C.}",
year = "2015",
month = "10",
day = "2",
doi = "10.1021/acs.jproteome.5b00703",
language = "English (US)",
volume = "14",
pages = "4394--4401",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples

AU - Hecht, Elizabeth S.

AU - Scholl, Elizabeth H.

AU - Walker, S. Hunter

AU - Taylor, Amber D.

AU - Cliby, William Arthur

AU - Motsinger-Reif, Alison A.

AU - Muddiman, David C.

PY - 2015/10/2

Y1 - 2015/10/2

N2 - An early-stage, population-wide biomarker for ovarian cancer (OVC) is essential to reverse its high mortality rate. Aberrant glycosylation by OVC has been reported, but studies have yet to identify an N-glycan with sufficiently high specificity. We curated a human biorepository of 82 case-control plasma samples, with 27%, 12%, 46%, and 15% falling across stages I-IV, respectively. For relative quantitation, glycans were analyzed by the individuality normalization when labeling with glycan hydrazide tags (INLIGHT) strategy for enhanced electrospray ionization, MS/MS analysis. Sixty-three glycan cancer burden ratios (GBRs), defined as the log10 ratio of the case-control extracted ion chromatogram abundances, were calculated above the limit of detection. The final GBR models, built using stepwise forward regression, included three significant terms: OVC stage, normalized mean GBR, and tag chemical purity; glycan class, fucosylation, or sialylation were not significant variables. After Bonferroni correction, seven N-glycans were identified as significant (p <0.05), and after false discovery rate correction, an additional four glycans were determined to be significant (p <0.05), with one borderline (p = 0.05). For all N-glycans, the vectors of the effects from stages II-IV were sequentially reversed, suggesting potential biological changes in OVC morphology or in host response.

AB - An early-stage, population-wide biomarker for ovarian cancer (OVC) is essential to reverse its high mortality rate. Aberrant glycosylation by OVC has been reported, but studies have yet to identify an N-glycan with sufficiently high specificity. We curated a human biorepository of 82 case-control plasma samples, with 27%, 12%, 46%, and 15% falling across stages I-IV, respectively. For relative quantitation, glycans were analyzed by the individuality normalization when labeling with glycan hydrazide tags (INLIGHT) strategy for enhanced electrospray ionization, MS/MS analysis. Sixty-three glycan cancer burden ratios (GBRs), defined as the log10 ratio of the case-control extracted ion chromatogram abundances, were calculated above the limit of detection. The final GBR models, built using stepwise forward regression, included three significant terms: OVC stage, normalized mean GBR, and tag chemical purity; glycan class, fucosylation, or sialylation were not significant variables. After Bonferroni correction, seven N-glycans were identified as significant (p <0.05), and after false discovery rate correction, an additional four glycans were determined to be significant (p <0.05), with one borderline (p = 0.05). For all N-glycans, the vectors of the effects from stages II-IV were sequentially reversed, suggesting potential biological changes in OVC morphology or in host response.

KW - cancer biomarker

KW - human plasma

KW - INLIGHT

KW - N-linked glycosylation

KW - ovarian cancer

KW - relative quantification

UR - http://www.scopus.com/inward/record.url?scp=84942861116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942861116&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.5b00703

DO - 10.1021/acs.jproteome.5b00703

M3 - Article

C2 - 26347193

AN - SCOPUS:84942861116

VL - 14

SP - 4394

EP - 4401

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 10

ER -